DUBLIN – U.S. protectionism, the looming specter of Brexit and the European Union's increasingly vocal stance on Ireland's corporate tax regime should all be weighing on Ireland's export-oriented biopharma sector at present, but the mood during the opening plenary of the Biopharma Ambition Conference Wednesday was upbeat, if not buoyant.